Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (DIA-AID)
A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277® in Newly Diagnosed Type 1 Diabetes Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1030
- Rudolfstiftung Hospital
-
-
-
-
-
Olomouc, Czech Republic, 775 20
- Faculty Hospital
-
Prague, Czech Republic, 150 06
- Faculty hospital Motol.
-
Praha, Czech Republic, 4 140 21
- IKEM/Diabetes Centre
-
-
-
-
-
Joensuu, Finland, 80100
- Pohjois-Karjala projektin tutkimussäätiö
-
Oulu, Finland, 90220
- Tutkimusyksikkö Oulu
-
Vantaa, Finland, 01300
- Diabetestutkimus
-
-
-
-
-
Grenoble, France, 38043
- CHU de GRENOBLE
-
Lyon, France, 69003
- Hôpital Edouard Herriot
-
Marseille, France, 13005
- Hôpital La Timone
-
Nimes, France, 30029
- CHU de Nîmes/ Hôpital Caremeau
-
-
-
-
-
Giessen, Germany, 35392
- Universitätsklinikum
-
Hannover, Germany, 30173
- Diabetes Centre for Children and Adolescents
-
Munich, Germany, 80804
- Institut für Diabetesforschung an der Klinik und Hochschulambulanz für Kinder- und Jugendmedizin
-
-
-
-
-
Athens, Greece, 11572
- Laiko Hospital
-
-
-
-
-
Holon, Israel, 58100
- Wolfson Medical Centre
-
Jerusalem, Israel, 91120
- Hadassah University Hospital
-
Petach Tikva, Israel, 49202
- Schneider Children's Medical Centre
-
-
-
-
-
Bari, Italy, 70124
- Universita' degli Studi di Bari
-
Palermo, Italy, 90127
- Ex Istituto di clinica medica
-
Rome, Italy, 00155
- University Campus Bio-Medico
-
Rome, Italy, 00161
- Università "La Sapienza"
-
Rozzano, Italy, 20089
- Istituto Clinico Humanitas
-
-
-
-
-
Cape Town, South Africa, 7129
- Helderberg Clinical Trials Unit
-
Cape Town, South Africa, 7925
- New Groote Schuur Hospital
-
Durban, South Africa, 4091
- 102 Parklands Medical Centre
-
Johannesburg, South Africa, 2198
- Centre for Diabetes and Endocrinology
-
Johannesburg, South Africa, 2193
- Donald Gordon Medical Center
-
-
-
-
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu
-
Lleida, Spain, 5198
- Hospital Universitari Arnau de Vilanova
-
Sabadell, Spain
- Hospital de Sabadell
-
Tenerife, Spain, 38010
- Hospital Nuestra señora de la Candelaria
-
-
-
-
-
London, United Kingdom, EC1A 7BE
- St. Bartholomew's Hospital
-
Shrewsbury, United Kingdom, SY3 8XQ
- Royal Shrewsbury Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A diagnosis of type 1 diabetes for up to 3 months at screening
- Insulin dependency
- Fasting C-peptide levels >= 0.22 nmol/L
- Presence of at least 1 of the diabetes-related autoantibodies (IA-2A, GAD or IA)
Exclusion Criteria:
- Pregnancy or intent to conceive in the next 2 years
- Significant diseases that could affect response to treatment, such as tumors, psychiatric disorders, substance abuse, severe allergies or diabetes-related complications.
- Patient has immune deficiency or receives immuno-suppressive or cytotoxic drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DiaPep277
DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
|
1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
|
|
Placebo Comparator: Placebo
Mannitol 40 mg in 0.5 mL lipid emulsion.
|
Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months
Time Frame: Baseline and 24 months
|
Beta-cell function, measured as change in stimulated C-peptide secretion measured 0, 2, 6, 10 and 20 minutes post administration [area under the curve (AUC), 0-20 minutes] at Baseline and 24 months, during a glucagon stimulation test (GST).
The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.
|
Baseline and 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Mixed-meal Stimulated C-peptide AUC at 24 Months
Time Frame: Baseline and 24 Months
|
Beta cell function, measured as stimulated C-peptide secretion from 0 to 120 min post administration AUC, at baseline and 24 month measurements in a mixed-meal tolerance test (MMTT).
The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.
|
Baseline and 24 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Paolo Pozzilli, MD, Universita Campus Bio-Medico, Rome
- Principal Investigator: Francois Bonici, MD, New Groote Schuur Hospital, Cape Town
- Principal Investigator: Thomas Linn, MD, Universitätsklinikum, Giessen
Publications and helpful links
General Publications
- Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA, Giordano C, Giorgino F, de Vries L, Mauricio D, Prochazka V, Wainstein J, Elias D, Avron A, Tamir M, Eren R, Peled D, Dagan S, Cohen IR, Pozzilli P; DIA-AID 1 Writing Group. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care. 2014;37(5):1392-400. doi: 10.2337/dc13-1391.
- Pozzilli P, Raz I, Peled D, Elias D, Avron A, Tamir M, Eren R, Dagan S, Cohen IR. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. Diabetes Care. 2014;37(5):1384-91. doi: 10.2337/dc13-1392. Epub 2014 Jan 9.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 901
- ISRCTN55429664
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.